2022-000174-25: Phase 2a, Random, double masked, Placebo-controlled, side by side group, multiple center study evaluating the success and safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% compared with Placebo in Subjects with Fuchs endothelial Corneal Dystrophy (FECD) |
|
|
| Not yet recruiting | 2 | 80 | Europe | STN1010904 Ophthalmic Suspension, STN1010904 (DE-109D), Eye drops | SANTEN INCORPORATED, Santen Inc. | Fuchs Endothelial Corneal Dystrophy (FECD) Dystrophie cornéenne endothéliale de Fuchs (FECD), Fuchs Endothelial Corneal Dystrophy (FECD) Dystrophie cornéenne endothéliale de Fuchs (FECD), Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
PHANTOM, NCT05376176: A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) |
|
|
| Active, not recruiting | 2 | 80 | Europe, US, RoW | STN1010904 ophthalmic suspension 0.03% BID, STN1010904 ophthalmic suspension 0.1% BID, Placebo (Vehicle) BID | Santen Inc., ActualEyes Inc. | Fuchs Endothelial Corneal Dystrophy | 05/25 | 05/25 | | |
